Manufacturer record

Glenmark Pharmaceuticals Ltd: regulatory record

Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories

9 batches manufactured by Glenmark Pharmaceuticals Ltd (Sikkim) were declared Not of Standard Quality between May 2021 and April 2025. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.

Records by type

9 records linked to Glenmark Pharmaceuticals Ltd in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.

0Banned or prohibited
0Recalled or suspended
9Failed a lab test
0Regulatory notice
Primary government sourceTier 1: government primary source

CDSCO drug alerts: Not of Standard Quality and spurious drugs

CDSCO · CDSCO monthly NSQ alerts, May 2021 to Apr 2025

View original document

Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.

9
NSQ batches since 2021
8
Products affected
Dissolution
Most common failure
Apr 2025
Latest alert

Flagged batches per year

2021 · 12022 · 12023 · 42024 · 22025 · 1

All flagged batches

Product Batch Reason declared NSQ Tested by Alert
Clotrimazole and Selenium Sulfide Suspension, candid tv 46230305Mfg 2023-12 · Exp 2025-11 Sample does not conform to label claim with respect to identification and the content of clotrimazole (Deemed to be spurious)Identification DTL MaduraiState lab Apr 2025
Telma H (Telmisartan 40 mg and Hydrochlorot hiazide 12.5mg Tablets IP) 18230080Mfg 2023-02 · Exp 2026-01 Dissolution & Assay of TelmisartanAssay Not applicableCDSCO lab Aug 2024
CANDITRAL 100 (ITRACONAZOLE CAPSULE B.P. 100 MG) 5230123Mfg 2023-01 · Exp 2025-06 THE SAMPLE DOES NOT COMPLY WITH B P REQUIREMENTS FOR DISSOLUTION TESTDissolution State Lab MaharashtraState lab Jun 2024
Ziten Tablets (Teneligliptin Tablets IP 20 mg) 18220672Mfg 2022-09 · Exp 2024-08 DissolutionDissolution CDTL ChennaiCDSCO lab Apr 2023
Telmisartan 40 mg and Amlodipine 5 mg Tablets IP (Telma-AM Tablets) 18220076Mfg 2022-01 · Exp 2024-12 Dissolution of TelmisartanDissolution RDTL ChandigarhState lab Mar 2023
Telma 40 (Telmisartan Tablets I.P. 40 mg) 18220015Mfg 2022-01 · Exp 2024-12 Identification & AssayAssay CDL KolkataCDSCO lab Feb 2023
Hydroxyzine HCl IP /BP 225004009Mfg 2022-08 · Exp 2027-07 Appearance of solutionOther CDTL MumbaiCDSCO lab Jan 2023
Telmisartan 40 mg and Hydrochlorothiazide 12.5 mg Tablets IP (TELMA H TABLETS) 18200994Mfg 2020-10 · Exp 2023-09 Assay of TelmisartanAssay RDTL ChandigarhState lab Feb 2022
Telmisartan 40 mg and Amlodipine 5 mg Tablets IP (TELMA-AM TABLETS) 5201874Mfg 2020-10 · Exp 2023-09 Dissolution of AmlodipineDissolution RDTL ChandigarhState lab May 2021

Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.